HIV vaccines: where we are and where we are going.
As the HIV-1 epidemic continues to spread world wide, the need for an effective vaccine remains urgent. Efforts to develop such a vaccine have been hampered by three main factors: (a) the extraordinary ability of the virus to mutate; (b) inability of most known specificities of anti-HIV antibodies to neutralise HIV primary isolates consistently; and (c) lack of understanding of the correlates of protective immunity to HIV infection. In view of the complex biology of HIV-host interactions, the most fruitful avenue may be development of multivalent HIV immunogens tailored to HIV isolates in specific geographical locations.
Haynes
B F
BF
Duke University AIDS Center, Durham, North Carolina, USA.
D016915:AIDS Vaccines / Q000276:immunology*; D000818:Animals; D015195:Drug Design; D015658:HIV Infections / Q000276:immunology*; D015497:HIV-1 / Q000187:drug effects / Q000276:immunology*; D006680:HLA Antigens / Q000276:immunology; D006801:Humans; D014614:Vaccines, Synthetic / Q000276:immunology
D016915:AIDS Vaccines; D006680:HLA Antigens; D014614:Vaccines, Synthetic